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Introduction {#sec1-1}
============

The hippocampus is one of the most vulnerable brain areas post-ischemia, especially its CA1 region. Pyramidal neurons in the hippocampal CA1 region were selectively lost 2 to 3 days after global cerebral ischemia, whereas other neurons in the same area were unaffected (Duan et al., 2011; Yan et al., 2012; Sun et al., 2018). In recent findings, neuronal damage was also observed in the hippocampal CA1 region after middle cerebral artery occlusion (MCAO), a condition that does not directly affect the hippocampus (Uchida et al., 2010; Jiao et al., 2011). The underlying mechanisms remain poorly understood. Previous studies, including our own, suggested that after transient focal cerebral ischemia astrocytes and microglia are swiftly activated and play complex roles in the infarct and peri-infarct regions, with both beneficial and detrimental effects (Jiao et al., 2011; Hu et al., 2012; Xu et al., 2016). This phenomenon has also been found in the hippocampal CA1 region after global ischemia (Lee et al., 2010; Rauš et al., 2013). However, it is not known how or when astrocytes and microglia change and what effect they exert in the hippocampal CA1 region after transient focal cerebral ischemia.

Under normal conditions, astrocytes and microglia are ubiquitously distributed, quiescent cell populations that reside in the central nervous system. One of the main characteristics of astrocytes and microglia is their swift activation in response to various pathologies, such as trauma, neurodegenerative diseases and ischemia. The hallmarks of their activation include proliferation, morphological changes and the release of cytokines and growth factors (Yuan et al., 2007; Uchida et al., 2010). Both cell types can be either neuroprotective or neurotoxic, depending on their morphology and their releasing factors (Chvátal et al., 2007; Wang et al., 2013).

Ilexonin A, extracted from the root of pubescent holly, Ilex pubescens, is a 3β-succinyl-18-dehydro-disodic ursolate (**[Figure 1](#F1){ref-type="fig"}**), which has been clinically used as cardiovascular drug. Our group has done a lot of research on the neuroprotective effect of ilexonin A. It has been shown to reduce the infarction volume and to improve neurological deficits after focal brain ischemia in adult rats (Zheng et al., 2011; Xu et al., 2016). Ilexonin A acts as a neuroprotector by promoting neural regeneration, enhancing the secretion of neurotrophic factors and mitigating cerebral edema (Sheng et al., 2009; Zheng et al., 2011). Our previous research shows that ilexonin A plays a neuroprotective role by regulating the activation of astrocytes and microglial cells in the peri-infarct area post-ischemia (Xu et al., 2016), and by activating wnt and notch signaling pathways (Zhang et al., 2016; Han et al., 2018). A previous study has shown that curcumin, another herbal component, had similar effects to ilexonin A, improving GFAP and nestin protein levels in the hippocampal CA1 region after ischemia (Zhang et al., 2011). In this study, we established the role of ilexonin A in activating astrocytes and microglia in the hippocampal CA1 region of the ipsilateral brain and determined the expression of nestin, TNF-α and IL-1β after ischemia/reperfusion. This study tested doses of 20, 40, and 80 mg/kg ilexonin A to develop a therapeutic strategy.

![Chemical structure of ilexonin A.](NRR-15-78-g002){#F1}

Materials and Methods {#sec1-2}
=====================

Animals and drug administration {#sec2-1}
-------------------------------

Male clean Sprague-Dawley rats aged 6--8 weeks old and weighing 250 ± 10 g were purchased from the Shanghai SLAC Laboratory Animal Co., Ltd., China (license No. SCXK (Hu) 2007-0005). These rats were randomly divided into six groups: (1) control, (2) sham, (3) ischemia, and ischemia groups treated with ilexonin A at (4) 20 mg/kg, (5) 40 mg/kg, or (6) 80 mg/kg. Each group has four subgroups (*n* = 6/subgroup) for each of the time following MCAO (1, 3, 7, and 14 days). Two rats in each subgroup were intraperitoneally injected with either 20, 40, or 80 mg/kg ilexonin A (Guangdong Boro Pioneer Pharmaceutical Group Co., Ltd., Huizhou, Guangdong Province, China; Product No. Z44023366) after ischemia/reperfusion. Rats in the control, sham and ischemia groups were intraperitoneally injected with an equal volume (2 mL) of saline. Our study was approved by the Animal Ethics Committee of Union Hospital of Fujian Medical University, China.

Procedure of transient focal cerebral ischemia {#sec2-2}
----------------------------------------------

Transient focal cerebral ischemia was induced by MCAO using the method developed by Longa et al. (1989). Rats were intraperitoneally anesthetized with 10% chloral hydrate (300 mg/kg). Blunt separation of the left common carotid artery, internal carotid artery and external carotid artery was performed through a ventral midline incision of the neck. The distal end of the external carotid artery branches was ligated and dissociated by electric coagulation. A nylon monofilament suture (diameter 0.26 mm) with a paraffin-rounded tip was inserted from the external carotid artery into the internal carotid artery for 18 ± 0.5 mm, to occlude the middle cerebral artery. The nylon suture was fixed and the incision was closed. After 2 hours of ischemia, the suture was withdrawn for reperfusion. Rats in the sham group underwent identical surgery, without the nylon suture that induced ischemia. Rats in the control group did not undergo surgery. The method of 2,3,5-triphenyltetrazolium chloride staining of MCAO was as published in our previous study (Xu et al., 2016).

Criteria for MCAO modeling {#sec2-3}
--------------------------

Following ischemia/reperfusion, neurological findings were evaluated at five levels of behavior based on Longa's method (Zhang et al., 2011), as follows: 4, no spontaneous walking with a depressed level of consciousness; 3, falling down to the right; 2, circling to the right; 1, failure to extend right forelimb fully; 0, no deficit. MCAO was considered successful in rats scoring 1--3 points. Dead or non-compliant animals were removed from the experiment.

Immunohistochemistry {#sec2-4}
--------------------

Rats were intraperitoneally anesthetized with 10% chloral hydrate (300 mg/kg) and lavaged with 100 mL of saline, followed by 200 mL of 0.1 M phosphate-buffered 4% paraformaldehyde, pH 7.4. Brains were isolated, fixed in the same fixative for 24 hours, and dehydrated in 15%, 20%, and 30% sucrose gradient in 0.1 M phosphate buffer, pH 7.4. These 8 μm-thick sections, cut by a cryomicrotome (MICROM HM525, Walldorf, Germany), were used for immunohistochemical examination. Immunohistochemistry was carried out according to the protocol provided by Elivision kit (1110219901, Fuzhou Maixin Biotechnology Development Co., Ltd., Fuzhou, China), with 1:5000 rabbit polyclonal anti-GFAP antibody (ab7260; Abcam, Cambridge, UK) to mark astrocytes, 1:100 goat polyclonal anti-Iba-1 antibody (ab5076; Abcam) to mark microglia, and 1:100 mouse monoclonal anti-rat nestin antibody (sc-33677; Santa Cruz Biotechnology, Dallas, TX, USA) to mark neural progenitor cells. After incubation overnight at 4°C, a negative control, 0.01 M phosphate-buffered saline was used in place of the primary antibody. The enzyme-labeled anti-mouse/rabbit polymers in the kit were incubated at room temperature for 30 minutes. A 3,3′-diaminobenzidine kit (Zhongshan Biotechnology, Beijing, China) was used to visualize the results. An optical microscope (CX40; Olympus, Tokyo, Japan) was used for image acquisition. Three sections of each brain of each group (*n* = 6) were viewed, and positive cells were evaluated by Imagine Pro Plus 5.0 (Media Cybernetics, Inc., Rockville, MD, USA) in 400× microscopic fields for each section in the middle part of the hippocampal CA1 region.

Western blot assay {#sec2-5}
------------------

Rats were lavaged with 100--200 mL saline after anesthesia with 10% chloral hydrate (300 mg/kg, intraperitoneally) and their brains were isolated. The hippocampal CA1 regions were disassociated in 10 μg/mL radioimmunoprecipitation assay lysis buffer containing phenylmethyl sulfonylfluoride (final concentration 0.01 M). The supernatant was collected after sonication and centrifugation at 14,000 × g at 4°C for 5 minutes. A 100 μg sample of total protein, as quantified by bicinchoninic acid protein quantitation, was diluted with lysis buffer, boiled for 5 minutes, and resolved on sodium dodecyl sulfate polyacrylamide gels with various percentages, depending on the molecular weight of the target protein. Following electrophoresis, proteins were transferred to nitrocellulose membranes at a constant current of 250--300 mA for 2 hours. The membranes were blocked in 5% non-fat milk in Tris-buffered saline/Tween-20 (pH 7.5, Tris-HCl 0.1 M, 0.05% Tween-20 and 0.9% NaCl) at room temperature for 1 hour and then incubated with the primary antibodies: rabbit polyclonal anti-GFAP (ab7260, 1:20,000; Abcam), goat polyclonal anti-Iba-1 (ab5076, 1:200; Abcam), mouse monoclonal anti-nestin (sc-33677, 1:300; Santa Cruz Biotechnology), or mouse monoclonal anti-β-actin (sc-47778, 1:2000; Santa Cruz Biotechnology) at 4°C overnight. After Tris-buffered saline/Tween-20 washes, membranes were incubated with 1:6000 peroxidase-conjugated rabbit anti-goat IgG (ZB-2306; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd., Beijing, China) at room temperature for 2 hours. Enhanced chemiluminescence detection reagents (KPL, Gaithersburg, MD, USA) were used to visualize the result. The band absorbance was measured using ImageMaster^®^ VDS gel imaging and analysis systems (alpha Innotech Corporation, San Leandro, USA), and normalized to the absorbance of the β-actin band, using grey levels.

Enzyme-linked immunosorbent assay {#sec2-6}
---------------------------------

Levels of TNF-α and IL-1β in collected supernatants (see above) were determined by standard enzyme-linked immunosorbent assay (ELISA), as per the supplier protocol (Boster, Wuhan, China). All assays were carried out in duplicate.

Statistical analysis {#sec2-7}
--------------------

All data, expressed as the mean ± SD, were analyzed by one-way analysis of variance using the SPSS 17.0 Software package (SPSS, Chicago, IL, USA). The differences between groups were analyzed using the least significant difference test for homogeneity of variance. A value of *P* \< 0.05 was considered statistically significant.

Results {#sec1-3}
=======

Astrocyte activation in the hippocampal CA1 region in an ischemia/reperfusion rat model with ilexonin A treatment {#sec2-8}
-----------------------------------------------------------------------------------------------------------------

GFAP-positive cells in CA1 were scattered in the control and sham groups. Astrocytes were activated swiftly after ischemia/reperfusion and their morphology changed: the soma swelled, the cytoplasm stained darkly and cell processes grew and thickened. Following ilexonin A treatment, the number of GFAP-positive cells increased at 1, 3, and 7 days post-ischemia/reperfusion, peaked at 7 days in the subgroup treated with 80 mg/kg ilexonin A, and had significantly decreased at 14 days (**Figure [2A](#F2){ref-type="fig"}** and **[B](#F2){ref-type="fig"}**). Western blot assay results confirmed the results of immunohistochemistry (**Figure [2C](#F2){ref-type="fig"}** and **[D](#F2){ref-type="fig"}**). Compared with the ischemia group, GFAP expression was significantly increased in the ilexonin A 40 mg/kg and 80 mg/kg groups (*P* \< 0.05). There were no significant differences in GFAP expression among the 20, 40 and 80 mg/kg ilexonin A groups. Changes in astrocyte morphology and protein expression were consistent with those observed in the peri-infarct region (data not shown).

![Astrocyte activation in the hippocampal CA1 region after ischemia/reperfusion and ilexonin A treatment.\
(A, B) GFAP immunostaining (arrows) in the hippocampal CA1 region at different time points after ischemia/reperfusion and treatment with 80 mg/kg ilexonin A (IA). (a--d) Ischemia group at 1, 3, 7 and 14 days post-reperfusion; (e--h) Ilexonin A 80 mg/kg group at 1, 3, 7 and 14 days (d) post-reperfusion (400×, scale bar: 50 μm). (C, D) The GFAP protein in the hippocampus was detected by western blot analysis (C) and analyzed in (D) using β-actin protein as an internal reference. a1, 3, 7, 14: Ischemia group at 1, 3, 7 and 14 days post-reperfusion; b1, 3, 7, 14: Ilexonin A 20 mg/kg group at 1, 3, 7 and 14 days post-reperfusion; c1, 3, 7, 14: Ilexonin A 40 mg/kg group at 1, 3, 7 and 14 days post-reperfusion; d1, 3, 7, 14: Ilexonin A 80 mg/kg group at 1, 3, 7 and 14 days post-reperfusion. Data are expressed as the mean ± SD. \**P* \< 0.05, *vs*. ischemia group (one-way analysis of variance followed by the least significant difference test).](NRR-15-78-g003){#F2}

Microglial activation in the hippocampal CA1 region in an ischemia/reperfusion rat model with ilexonin A administration {#sec2-9}
-----------------------------------------------------------------------------------------------------------------------

Microglial cells in the hippocampal CA1 region remain quiescent after ischemia/reperfusion. Following treatment with ilexonin A, Iba-1 positive cells became activated and distributed in a specific pattern in the pyramidal layer (**Figure [3A](#F3){ref-type="fig"}** and **[B](#F3){ref-type="fig"}**). Compared with the ischemia group, the number of Iba-1 positive cells in the ilexonin A 40 mg/kg and 80 mg/kg groups were increased at the time points of 3, 7 and 14 days (*P* \< 0.05). This change was most obvious in the ilexonin A 80 mg/kg group at 7 days after ischemia/reperfusion compared with the ilexonin A 20 mg/kg or 40 mg/kg groups (*P* \< 0.01). The morphology of reactive microglia in the ilexonin A-treated groups did not change into a macrophage-like shape, but rather into bushy shapes. Western blot analysis of Iba-1 protein is shown in **Figure [3C](#F3){ref-type="fig"}** and **[D](#F3){ref-type="fig"}**.

![Microglial activation in the hippocampal CA1 region after ischemia/reperfusion and ilexonin A treatment.\
(A, B) Iba-1 immunostaining (arrows) in the hippocampal CA1 region at different time points after ischemia/reperfusion and treatment with 80 mg/kg ilexonin A (IA). (a--d) Ischemia group at 1, 3, 7 and 14 days post-reperfusion; (e--h) Ilexonin A 80 mg/kg group at 1, 3, 7 and 14 days post-reperfusion (400×, scale bar: 50 μm). The Iba-1 protein in the hippocampus was detected by western blot assay (C) and analyzed in (D) using β-actin protein as an internal reference. a1, 3, 7, 14: Ischemia group at 1, 3, 7 and 14 days (d) post-reperfusion; b1, 3, 7, 14: Ilexonin A 20 mg/kg group at 1, 3, 7 and 14 days post-reperfusion; c1, 3, 7, 14: Ilexonin A .40 mg/kg group at 1, 3, 7 and 14 days post-reperfusion; d1, 3, 7, 14: Ilexonin A 80 mg/kg group at 1, 3, 7 and 14 days post-reperfusion. Data are expressed as the mean ± SD. \**P* \< 0.05, *vs*. ischemia group; \#*P* \< 0.01, *vs*. IA 20 and IA 40 mg/kg groups (one-way analysis of variance followed by the least significant difference test).](NRR-15-78-g004){#F3}

Proliferation of neuronal stem cells in the hippocampal CA1 region in an ischemia/reperfusion rat model after ilexonin A treatment {#sec2-10}
----------------------------------------------------------------------------------------------------------------------------------

No nestin-positive cells were observed in the hippocampal CA1 region of either the control or sham groups. The number of nestin-positive cells increased significantly after ischemia/reperfusion, increasingly more with increasing doses of ilexonin A (**Figure [4A](#F4){ref-type="fig"}** and **[B](#F4){ref-type="fig"}**). Compared with the ischemia group, the number of nestin-positive cells was significantly different in the ilexonin A 80 mg/kg group at each time point (*P* \< 0.05). The number of nestin-positive cells in the ilexonin A 80 mg/kg group was also significantly greater than those in the ilexonin A 20 mg/kg or 40 mg/kg groups (*P* \< 0.05). Two types of nestin-positive cells were detected, characterized by different morphology, different distribution and different activation (**[Figure 5A](#F5){ref-type="fig"}**). The first type stained lighter and had hypertrophic soma and slender cellular processes. They were observed mostly in the ischemia group and with only a few in the ilexonin A 20 mg/kg group at 3 days after ischemia/reperfusion. They were specifically distributed in the pyramidal cell layer of the hippocampal CA1 region but also appeared in different parts of the CA1 region at different times after ischemia/reperfusion. Nestin-positive cells appeared increasingly closer to the center line of the brain from 3 to 14 days, while the total number of cells decreased over the same period of time (**[Figure 5B](#F5){ref-type="fig"}**). The second type of cells stained darker and had smaller soma and thicker cellular processes, similar to astrocytes. They were non-specifically distributed around the CA1 region. After treatment with ilexonin A, the number of the second type of nestin-positive cells was significantly increased in the hippocampal CA1 region, especially in the ilexonin A 80 mg/kg group at 3 and 7 days post-ischemia/reperfusion. The two types of nestin-positive cells did not co-localize spatially and temporally, but rather had appeared sequentially in the reperfused tissue. The first type peaked at 3 days, whereas the second peaked at 7 days after treatment with ilexonin A. Changes in nestin protein levels are shown in **Figure [4C](#F4){ref-type="fig"}** and **[D](#F4){ref-type="fig"}**.

![Neuronal stem cell proliferation in the hippocampal CA1 region after ischemia/reperfusion and administration of ilexonin A.\
(A, B) Nestin immunostaining (arrows) in the hippocampal CA1 region at different time points after ischemia/reperfusion and administration of ilexonin A (IA). (a--d) Ischemia group at 1, 3, 7 and 14 days post-reperfusion; (e--h) Ilexonin A 80 mg/kg group at 1, 3, 7 and 14 days post-reperfusion (scale bar: 50 μm). The nestin protein in the hippocampus was detected by western blot analysis (C) and analyzed in (D) using β-actin protein as an internal reference. a1, 3, 7, 14: Ischemia group at 1, 3, 7 and 14 days post-reperfusion; b1, 3, 7, 14: Ilexonin A 20 mg/kg group at 1, 3, 7 and 14 days post-reperfusion; c1, 3, 7, 14: Ilexonin A 40 mg/kg group at 1, 3, 7 and 14 days post-reperfusion; d1, 3, 7, 14: Ilexonin A 80 mg/kg group at 1, 3, 7 and 14 days post-reperfusion. Data are expressed as the mean ± SD. \**P* \< 0.05, *vs*. ischemia group; \#*P* \< 0.05, *vs*. IA 20 and IA 40 mg/kg groups (one-way analysis of variance followed by the least significant difference test).](NRR-15-78-g005){#F4}

![Characteristics of nestin-positive cells in the hippocampal CA1 region.\
(A) Different morphologies of nestin-positive cells (arrows) in the ischemia group at 14 days. (B) Nestin-positive cells (arrows) appeared in different parts of the CA1 region at different time points after ischemia/reperfusion. (a--c) 3, 7, 14 days after MCAO. Original magnification: 400×; scale bars: 50 μm. IA: Ilexonin A. MCAO: middle cerebral artery occlusion.](NRR-15-78-g006){#F5}

TNF-α and IL-1β concentrations in the hippocampal tissue in an ischemia/reperfusion rat model after ilexonin A administration {#sec2-11}
-----------------------------------------------------------------------------------------------------------------------------

The concentrations of TNF-α and IL-1β in the hippocampal tissue increased continuously with time after reperfusion. TNF-α and IL-1β concentrations were significantly inhibited by ilexonin A, especially after administration at 80 mg/kg dose, compared with the ischemia group (*P* \< 0.01; **[Figure 6](#F6){ref-type="fig"}**). The effect in the ilexonin A 80 mg/kg group was significantly greater than that in the ilexonin A 20 mg/kg and 40 mg/kg groups at 14 days (*P* \< 0.05).

![Concentration of TNF-α and IL-1β in the hippocampal tissue after ischemia/reperfusion and IA administration as determined by enzyme linked immunosorbent assay.\
TNF-α (A) and IL-1β (B) concentrations were measured at 1, 3, 7 and 14 days after ischemia/reperfusion. Data are expressed as the mean ± SD. \**P* \< 0.01, *vs*. ischemia group (one-way analysis of variance followed by the least significant difference test). \#*P* \< 0.05, *vs*. IA 20 and IA 40 mg/kg groups. IA: Ilexonin A; IL-1β: interleukin 1β; TNF-α: tumor necrosis factor-α.](NRR-15-78-g007){#F6}

Discussion {#sec1-4}
==========

Unlike global cerebral ischemia or forebrain ischemia, transient focal cerebral ischemia induced by MCAO does not primarily affect the hippocampus. However, delayed neuronal death occurred in the pyramidal layer of the hippocampal CA1 region (Uchida et al., 2010; Jiao et al., 2011). Previous studies have suggested that neuroglial cells undergo dynamic changes: microglia were immediately activated and specifically distributed in the pyramidal layer, while astrocytes were activated later and distributed around the pyramidal layer. These changes were strongly associated with the delayed neuronal death that occurred following global cerebral ischemia (Duan et al., 2011; Yan et al., 2012; Lee et al., 2019). In our study, gliocytes that responded to delayed neuronal death after transient focal cerebral ischemia, showed different characteristics from those mentioned above. This may be due to the microenvironment created by the combination of blood reperfusion and ilexonin A.

Results from our study showed that astrocytes were activated rapidly around the pyramidal layer after ischemia/reperfusion, which is consistent with previous studies (Uchida et al., 2010; Jiao et al., 2011). However, the intensity of astrocyte activation in the hippocampus is weaker than in other peri-infarct regions. Ilexonin A plays a dual role, by either enhancing the activation of astrocytes in the early stages (1, 3, 7 days post-MCAO) or reducing the formation of glial scars at a later stage (14 days post-MCAO). It is accepted that reactive astrocytes can play a protective role in brain ischemia (Jeong et al., 2013). Some astrocytes acquire stem cell properties after injury and hence may differentiate to cell types needed to initiate repairs (Shin et al., 2013). They release neurotrophic factors such as glia-derived neurotrophic factor, neurotrophin receptors such as TrkB (a receptor for brain-derived neurotrophic factor), antioxidants and extracellular matrix proteins to promote functional repair (Lin et al., 2006; Tonchev et al., 2008; Ding et al., 2009). They were also shown to be involved in the neurovascular remodeling after ischemia/reperfusion (Hayakawa et al., 2010; Jing et al., 2013). The infarct volume expanded 2--3 fold when the activation of astrocytes was rescinded in deficient mutant mice (Li et al., 2008). However, reactive astrocytes proliferating in later stages played an key role in the formation of the glial scar, which promoted morphological repair of the central nervous system, but inhibited functional recovery (Davies et al., 1999). Therefore, the dual effects of ilexonin A provide a favorable condition for neuronal restoration.

Microglia are activated and proliferate swiftly after ischemia/reperfusion in the peri-infarction region and their morphology changes to rod-like or to amoeba-like cells, which are difficult to distinguish from blood-derived macrophages. After treatment with ilexonin A, the number of amoeba-like cells remarkably decreased, but the number of rod-like cells increased (Xu et al., 2016). Unlike microglia in the peri-infarction region, those in the hippocampal CA1 region were not activated after ischemia/reperfusion, but were activated after subsequent administration of ilexonin A. Previous studies indicated that different brain injuries led to microglia showing different phenotypes and performing different functions (Hu et al., 2012). It has been suggested that their functions (neurotoxic or neuroprotective) could be configured by the equilibrium among various microglial factors (Ekdahl et al., 2009; Wang et al., 2013). Recent *in vivo* and *in vitro* studies have suggested that activation and proliferation of resident microglia were essential for neuronal survival. Selective ablation of proliferating microglia or attenuated acute activation of microglia exacerbated the ischemic injury. Possibly linked to a reduction in the secretion of neurotrophic factors and neuronal plasticity proteins, such as glial cell-derived neurotrophic factor and insulin-like growth factor-1 (Montero et al., 2009; Arroba et al., 2011; Wang et al., 2013). These activated rod-like microglial cells may play a protective role against cerebral ischemia/reperfusion injury, however, further research is required to establish this role. Iba-1 labelling of microglia does not clearly differentiate between M1 and M2 microglial cell types; therefore, we plan to use CD86 and CD206 as markers to investigate the microglial cell type in a future study.

Neural stem cells are static in the intact brain. After brain injury, they begin to proliferate, undergo targeted migration, and differentiate into neurons or gliocytes necessary for neural regeneration and neurologic recovery (Liu et al., 2009). Previous findings suggested that new neurons were observed in the dentate subgranular zone, rostra subventricular zone and, recently, in the cerebral cortex after ischemia/reperfusion (Kim et al., 2009; Yao et al., 2009). Furthermore, ilexonin A enhanced the cortical differentiation of neural stem cells following transient focal cerebral ischemia (Zheng et al., 2011).

In this study, we found two types of nestin-positive neurons with different morphology distribution, and temporal expression after ischemia/reperfusion. Cerebral ischemic injury has induced mature neurons in the cerebral cortex to return to a naive state and re-express embryonic phase proteins (Schmidt-Kastner et al., 1997; Shen et al., 2008; Matsuda et al., 2013). Therefore, the first type of nestin-positive cells, found only in the ischemic model groups, may be mature neurons that start expressing nestin protein. This indicates that neurons may have a self-defense mechanism against ischemic injury. The spatio-temporal distribution of the second type of nestin-positive cells in the ischemic hippocampus mirrored that of astrocytes after ischemia/reperfusion and treatment with ilexonin A (Tao et al., 2014). Previous studies have indicated that reactive astrocytes assisted with neural stem cell proliferation and differentiation and even acquired the capacity to generate neurons (Kronenberg et al., 2010; Shin et al., 2013). Axonal growth cones grew only in the presence of healthy astrocytes but not in areas of injured astrocytes (Takano et al., 2009; Jing et al., 2013). This further confirms the neuroprotective effect of reactive astrocytes immediately after ischemia/reperfusion and indicates that ilexonin A may promote neuronal damage repair in the hippocampal CA1 region by inducing the proliferation of neural stem cells. However, it is unclear why the two types of nestin-positive cells do not co-localize.

TNF-α and IL-1β are factors secreted by activated gliocytes and monocytes/macrophages, which migrated from the peripheral blood due to increased permeability of the blood-brain barrier after ischemia/reperfusion. TNF-α and IL-1β promote and aggravate post-ischemic inflammation, via direct damage or indirectly by inducing the expression of other inflammation mediators. Blockers against both TNF-α and IL-1β remarkably reduced the volume of infarction after ischemia/reperfusion (Intiso et al., 2004; Caso et al., 2007). Our study also indicated that inflammation may play an important role in the delayed neuronal death occurring in the hippocampal CA1 region and that this inflammation is inhibited by ilexonin A. This result further confirms that reactive astrocytes and microglia exert neuroprotective effects after focal cerebral ischemia/reperfusion.

Our previous studies found that ilexonin A exerted the strongest neuroprotective effect in the peri-infarct region after focal cerebral ischemia/reperfusion at the dose of 40 mg/kg (Zheng et al., 2011; Xu et al., 2016). However, in this study, ilexonin A produced the best results at 80 mg/kg. This suggests that cells around the ischemic core may be more sensitive than those of the hippocampus, after the ischemia has occurred.

In conclusion, activation of astrocytes and microglia is associated with neuronal damage in the hippocampal CA1 region and may play a neuroprotective role after transient focal cerebral ischemia. Ilexonin A has a neuroprotective effect, probably through regulation of astrocyte and microglial activation, and thus promotes neural stem cell proliferation and reduces secretion of pro-inflammatory factors.

**Conflicts of interest:** *None declared.*

**Financial support:** *This study was supported by the Natural Science Foundation of Fujian Province of China, No. 2014J01327; the Program for New Century Excellent Talents in Colleges and Universities of Fujian Province of China, No. NCETFJ 0704; the Professorial Academic Development Foundation of Fujian Medical University of China, No. JS09014 (all to GYZ). The funders did not participate in data collection and analysis, article writing or submission.*

**Institutional review board statement:** *The experiments were approved by the Animal Ethics Committee of Fujian Medical University Union Hospital, China.*

**Copyright license agreement:** *The Copyright License Agreement has been signed by all authors before publication.*

**Data sharing statement:** *Datasets analyzed during the current study are available from the corresponding author on reasonable request.*

**Plagiarism check:** *Checked twice by iThenticate.*

**Peer review:** *Externally peer reviewed.*

***Funding:*** *This study was supported by the Natural Science Foundation of Fujian Province of China, No. 2014J01327; the Program for New Century Excellent Talents in Colleges and Universities of Fujian Province of China, No. NCETFJ-0704; the Professorial Academic Development Foundation of Fujian Medical University of China, No. JS09014 (all to GYZ).*

C-Editor: Zhao M; S-Editors: Yu J, Li CH; L-Editors: Dawes EA, Raye W, Qiu Y, Song LP; T-Editor: Jia Y

[^1]: **Author contributions:** *Study design and experiment implementation: ALX; project supervisor and study coordinator: GYZ; model establishment, immunostaining, western blot assay, and enzyme linked immunosorbent assay: ALX, HYY, QJ; critical commentator: XDC; data collection and analysis, result interpretation and paper writting: ALX. All authors approved the final version of the paper.*
